Clinical trial
A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
NCT02898207 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 19, 2017
- Completion date
- January 14, 2022
- Enrollment
- 28 (actual)
- Sites
- 8
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic high grade fallopian tube serous adenocarcinoma, metastatic malignant solid neoplasm, metastatic primary peritoneal serous adenocarcinoma, metastatic triple-negative breast carcinoma, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, recurrent breast carcinoma, recurrent high grade fallopian tube serous adenocarcinoma, recurrent high grade ovarian serous adenocarcinoma, recurrent primary peritoneal high grade serous adenocarcinoma, recurrent triple-negative breast carcinoma, refractory fallopian tube serous adenocarcinoma, refractory ovarian serous adenocarcinoma, refractory primary peritoneal serous adenocarcinoma, refractory triple-negative breast carcinoma, unresectable high grade fallopian tube serous adenocarcinoma, unresectable malignant solid neoplasm, unresectable primary peritoneal serous adenocarcinoma